Pipeline
March Biosciences is dedicated to revolutionizing patient care by discovering and exploiting high-impact targets for cancer immunotherapy. Our lead asset, MB-105, is designed to treat relapse/refractory T-cell malignancies, currently with no effective and curative alternative treatments
CAR-T Therapy
Chimeric antigen receptor (CAR) T-cells are a powerful new therapeutic option where T-cells are engineered to specifically target key antigens on tumor cells. This boosts the natural function of T-cells against cancer cells.
1. Collection of T-cells:
leukapheresis is used to isolate T-cells from a patient’s blood.
2. Genetic modification of T-cells:
The patients’ T-cells are genetically engineered in a laboratory to express the CAR, specifically designed to selectively recognize antigens on the cancer cells’ surface.
3. Expansion and activation of CAR T-cells:
The modified T-cells are expanded to increase their numbers and activated to boost their anti-cancer activity.
4. Infusion of CAR T-cells:
Following expansion and activation, the CAR T-cells are infused back into the patient’s bloodstream intravenously.
The engineered CAR-T cells will then circulate, target, and eliminate cancer cells expressing the target antigen.
Ongoing Trials
March Biosciences is currently supporting a Phase 2 study (NCT06534060) evaluating the autologous CD5 CAR-T therapy (MB-105), an investigational treatment for patients with CD5+ relapsed or refractory T-cell lymphoma (TCL). This Phase 2 study builds upon promising initial results obtained from the Phase 1 clinical trial being conducted at Baylor College of Medicine (BCM).
The Phase 1 trial (NCT03081910) at BCM continues to enroll patients with relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma (T-ALL/T-LBL) through physician referrals.
For more information on enrolling TCL patients in the ongoing Phase 2 study supported by March Biosciences, please visit our clinical trials page
News & Publications
Read more about how March Biosciences’ research has impacted the medical community.